Drug profile · INN
zanubrutinib
BRUKINSA
zanubrutinib (BRUKINSA) is a tyrosine-protein kinase btk inhibitor. Associated with BEONE MEDICINES AUS PTY LTD. Route of administration: oral. Current US regulatory status: approved.
Drug details — zanubrutinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 44
- Data quality
- 0.89
Quick answer
zanubrutinib (BRUKINSA) is a tyrosine-protein kinase btk inhibitor. Associated with BEONE MEDICINES AUS PTY LTD. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase BTK inhibitor
Primary target: Tyrosine-protein kinase BTK
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is zanubrutinib?
zanubrutinib (BRUKINSA) is a tyrosine-protein kinase btk inhibitor. Associated with BEONE MEDICINES AUS PTY LTD. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for zanubrutinib?
BRUKINSA is a marketed brand name for zanubrutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zanubrutinib?
zanubrutinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.